Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 20 of 54

1.

Design, synthesis, and DNA sequence selectivity of formaldehyde-mediated DNA-adducts of the novel N-(4-aminobutyl) acridine-4-carboxamide.

Ankers EA, Evison BJ, Phillips DR, Brownlee RTC, Cutts SM.

Bioorg Med Chem Lett. 2014 Dec 15;24(24):5710-5715. doi: 10.1016/j.bmcl.2014.10.062. Epub 2014 Oct 23.

PMID:
25453806
2.

A novel small molecule hybrid of vorinostat and DACA displays anticancer activity against human hormone-refractory metastatic prostate cancer through dual inhibition of histone deacetylase and topoisomerase I.

Yu CC, Pan SL, Chao SW, Liu SP, Hsu JL, Yang YC, Li TK, Huang WJ, Guh JH.

Biochem Pharmacol. 2014 Aug 1;90(3):320-30. doi: 10.1016/j.bcp.2014.06.001. Epub 2014 Jun 7.

PMID:
24915421
3.

In vitro-in vivo correlation for intrinsic clearance for drugs metabolized by human aldehyde oxidase.

Zientek M, Jiang Y, Youdim K, Obach RS.

Drug Metab Dispos. 2010 Aug;38(8):1322-7. doi: 10.1124/dmd.110.033555. Epub 2010 May 5.

PMID:
20444863
4.

Early tumor drug pharmacokinetics is influenced by tumor perfusion but not plasma drug exposure.

Saleem A, Price PM.

Clin Cancer Res. 2008 Dec 15;14(24):8184-90. doi: 10.1158/1078-0432.CCR-08-1324.

5.

Gateways to clinical trials.

BayƩs M, Rabasseda X, Prous JR.

Methods Find Exp Clin Pharmacol. 2004 Mar;26(2):129-61.

PMID:
15071612
6.

Pharmacokinetics of radiolabelled anticancer drugs for positron emission tomography.

Hutchinson OC, Collingridge DR, Barthel H, Price PM, Aboagye EO.

Curr Pharm Des. 2003;9(11):917-29. Review.

PMID:
12678875
7.

Individual variation in hepatic aldehyde oxidase activity.

Al-Salmy HS.

IUBMB Life. 2001 Apr;51(4):249-53.

9.

Comparative biodistribution and metabolism of carbon-11-labeled N-[2-(dimethylamino)ethyl]acridine-4-carboxamide and DNA-intercalating analogues.

Osman S, Rowlinson-Busza G, Luthra SK, Aboagye EO, Brown GD, Brady F, Myers R, Gamage SA, Denny WA, Baguley BC, Price PM.

Cancer Res. 2001 Apr 1;61(7):2935-44.

10.
11.

Ring-substituted 11-oxo-11H-indeno[1,2-b]quinoline-6-carboxamides with similar patterns of cytotoxicity to the dual topo I/II inhibitor DACA.

Deady LW, Desneves J, Kaye AJ, Thompson M, Finlay GJ, Baguley BC, Denny WA.

Bioorg Med Chem. 1999 Dec;7(12):2801-9.

PMID:
10658584
12.

Cellular uptake of N-[2-(dimethylamino)ethyl]acridine-4-carboxamide (DACA).

Haldane A, Finlay GJ, Hay MP, Denny WA, Baguley BC.

Anticancer Drug Des. 1999 Jun;14(3):275-80.

PMID:
10500502
13.

Carbamate analogues of amsacrine active against non-cycling cells: relative activity against topoisomerases IIalpha and beta.

Turnbull RM, Meczes EL, Perenna Rogers M, Lock RB, Sullivan DM, Finlay GJ, Baguley BC, Austin CA.

Cancer Chemother Pharmacol. 1999;44(4):275-82.

PMID:
10447574
14.
15.

Metabolism of N-[2-(dimethylamino)ethyl]acridine-4-carboxamide in cancer patients undergoing a phase I clinical trial.

Schofield PC, Robertson IG, Paxton JW, McCrystal MR, Evans BD, Kestell P, Baguley BC.

Cancer Chemother Pharmacol. 1999;44(1):51-8.

PMID:
10367749
16.

Plasma pharmacokinetics of N-[2-(dimethylamino)ethyl]acridine-4-carboxamide in a phase I trial.

Kestell P, Dunlop IC, McCrystal MR, Evans BD, Paxton JW, Gamage RS, Baguley BC.

Cancer Chemother Pharmacol. 1999;44(1):45-50.

PMID:
10367748
17.

Phase I study of the cytotoxic agent N-[2-(dimethylamino)ethyl]acridine-4-carboxamide.

McCrystal MR, Evans BD, Harvey VJ, Thompson PI, Porter DJ, Baguley BC.

Cancer Chemother Pharmacol. 1999;44(1):39-44.

PMID:
10367747
18.

5,7-Disubstituted analogues of the mixed topoisomerase I/II poison N-[2-(dimethylamino)ethyl]acridine-4-carboxamide (DACA): DNA binding and patterns of cytotoxicity.

Spicer JA, Finlay GJ, Baguley BC, Velea L, Graves DE, Denny WA.

Anticancer Drug Des. 1999 Feb;14(1):37-45.

PMID:
10363026
19.

Supplemental Content

Loading ...
Support Center